ComorosTuberculosis profile
Population  2016 <1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.051 (0.031–0.078) 6.5 (3.8–9.8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.41 (0.26–0.59)
Incidence  (includes HIV+TB) 0.28 (0.18–0.39) 35 (22–49)
Incidence (HIV+TB only) <0.01 (<0.01–0.013) 1.1 (0.71–1.6)
Incidence (MDR/RR-TB)** 0.045 (<0.01–0.081) 5.7 (1.1–10)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.015 (<0.01–0.02) 0.089 (0.054–0.12) 0.1 (0.063–0.14)
Males 0.015 (<0.01–0.021) 0.16 (0.095–0.22) 0.17 (0.1–0.24)
Total 0.03 (0.018–0.042) 0.25 (0.15–0.34) 0.28 (0.18–0.39)
TB case notifications, 2016  
Total cases notified 313
Total new and relapse 163
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status <1%
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 59% (41–91)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.21 (0.1–0.33)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 2 100%
          - on antiretroviral therapy 0 0%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  32
(3–62)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance   <1% 1
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 1, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 91% 74
Previously treated cases, excluding relapse, registered in 2015    
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014   0
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 0%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
9.7% (8.9–11)
TB financing, 2017  
National TB budget (US$ millions) <1
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data